Bell M J, Bishara L D
Department of Medicine, Sunnybrook Health Science Centre, University of Toronto, Ontario, Canada.
J Rheumatol. 1998 Oct;25(10):2026-8.
We describe a case of Stevens-Johnson syndrome (SJS) associated with oxaprozin ("Daypro"), a relatively new nonsteroidal antiinflammatory drug (NSAID) of the propionic acid group. Our literature review shows that among the NSAID associated with SJS, oxicams have the highest risk. The risk is low for the propionic acid group. Indeed, the prevalence of their use was too low to permit an analysis of individual drugs. This is the first reported case of SJS associated with oxaprozin. Although the patient we describe survived the reaction, we think it is important to report such a potentially fatal reaction to a relatively newly available medication.
我们描述了一例与奥沙普秦（商品名“Daypro”）相关的史蒂文斯-约翰逊综合征（SJS）病例，奥沙普秦是丙酸类一种相对较新的非甾体抗炎药（NSAID）。我们的文献综述表明，在与SJS相关的NSAID中，恶丙嗪类风险最高。丙酸类的风险较低。实际上，它们的使用发生率过低，无法对单一药物进行分析。这是首例报道的与奥沙普秦相关的SJS病例。尽管我们描述的患者在该反应中幸存下来，但我们认为报告这种对一种相对较新上市药物的潜在致命反应很重要。
